As the world’s third largest pharmaceutical market, Japan accounted for approximately 6% of the $1.5tn in global ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...

Big hats, no cattle When different people see the same thing differently, it’s often because they’re looking at different ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice Research conducted ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare ...

If you are struggling to navigate the complexity of early commercialisation, rest assured, you are not alone. Clinical trial ...

In theory, the principles of omnichannel – personalised content through the right channels to maximise customer experience – ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

For most of us working in healthcare communications, the best buzz is when the work has clearly reached those who are most in ...